

5TH EDITION

INNOVATIVE THERAPY,
MONOCLONAL ANTIBODIES
and beyond

Friday, 30 January 2015

Milan

Fondazione IRCCS Istituto Nazionale dei Tumori

Via Venezian, 1



FONDAZIONE IRCCS
ISTITUTO NAZIONALE
DEI TUMORI

Sistema Sanitario  Regione
Lombardia

Patronage requested

Faculty



FONDAZIONE IRCCS
ISTITUTO NAZIONALE
DEI TUMORI

Sistema Sanitario  Regione
Lombardia

NIBIT

Network Italiano per la Bioterapia dei Tumori



A. ANICHINI (MILAN, ITALY)

L. CERCHIETTI (NEW YORK, USA)

M.P. COLOMBO (MILAN, ITALY)

P. CORRADINI (MILAN, ITALY)

F. DE BRAUD (MILAN, ITALY)

M. DEL VECCHIO (MILAN, ITALY)

M. DI NICOLA (MILAN, ITALY)

G. DOTTI (HOUSTON, USA)

M. FIGINI (MILAN, ITALY)

G. INGHIRAMI (NEW YORK, USA)

M. MASSAIA (TURIN, ITALY)

A. RAMBALDI (BERGAMO, ITALY)

Presentation

Bio-immunotherapy of cancer is providing compelling proofs of clinical success in the comprehensive treatment of human malignancies.

The increasing knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, allowed us to identify and apply more effective anti-cancer biological and immunological treatments. To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorithms of several different tumors. Furthermore, elucidating resistance mechanisms and exploiting cancer vulnerabilities to therapeutics will ultimately improve cancer therapy and patient care.

For these reasons, a multidisciplinary approach, including clinical and pre-clinical professionals, is required.

This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.

Friday, 30 January 2015

WELCOME COFFEE

- 08.00-09.00 Registration
09.00-09.10 Welcome remarks of Authorities
09.10 Introduction • **M. Di Nicola** and **M. Del Vecchio** (Milan, Italy)

I SESSION: PRECLINICAL ASSAYS AND NOVEL BIOTARGETS

Chairmen: **G. Inghirami** (New York, USA), **M.P. Colombo** (Milan, Italy)

- 09.20-09.50 Humanized mice as preclinical model to guide targeted cancer therapy and drug development
G. Inghirami (New York, USA)
09.50-10.00 Discussion
10.00-10.30 OX-40 is a fitness adaptor for T cells in the tumor microenvironment • **M. Colombo** (Milan, Italy)
10.30-10.40 Discussion
10.40-11.10 Heat shock proteins and tumorigenesis • **L. Cerchiatti** (New York, USA)
11.10-11.20 Discussion
11.20-11.50 Rationale for immunotherapeutic combinations • **A. Anichini** (Milan, Italy)
11.50-12.00 Discussion

Keynote Lecture

- 12.00-12.45 Immune check-point inhibitors: clinical experience • **F. De Braud** (Milan, Italy)
12.45-14.00 *BUFFET LUNCH*

II SESSION: MONOCLONAL ANTIBODIES, CELL THERAPIES AND TK INHIBITORS

Chairmen: **M. Massaia** (Turin, Italy), **M. Di Nicola** (Milan, Italy)

- 14.00-14.30 Drug-conjugated antibody: Brentuximab and CD30+ hematological tumors • **P. Corradini** (Milan, Italy)
14.30-14.40 Discussion
- 14.40-15.50 Bispecific monoclonal antibody
1. Principles and novel targets • **M. Figini** (Milan, Italy)
2. Blinatumumab: clinical results • **A. Rambaldi** (Bergamo, Italy)
- 15.50-16.00 Discussion
- 16.00-16.30 CAR-T cell therapies from hematologic malignancies to solid tumors • **G. Dotti** (Houston, USA)
16.30-16.40 Discussion
- 16.40-17.10 Targeted therapies in melanoma • **M. Del Vecchio** (Milan, Italy)
17.10-17.20 Discussion
- 17.20 Conclusions • **M. Di Nicola** (Milan, Italy)

General Informations

CONGRESS VENUE

Aula Magna - Fondazione IRCCS
Istituto Nazionale dei Tumori
Via Venezian, 1 - MILAN

SCIENTIFIC COMMITTEE

Massimo Di Nicola

Michele Del Vecchio

Medical Oncology Department

*Fondazione IRCCS Istituto Nazionale dei Tumori
Milan*

ORGANIZING SECRETARIAT



Nadirex International Srl
Via Riviera 39 · 27100 Pavia
Tel. +39.0382.525714/35
Fax +39.0382.525736
E-mail: info@nadirex.com

CME PROVIDER NR. 265

Nadirex International Srl



CME

The request for CME credits has been submitted to the Italian Ministry of Health.

ID Nr. 265-112872 - CME credits: Nr. 8,5

The Congress is intended for the following figures:

- **Physician** (*Ematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine*)
- **Biologist - Nurse - Biomedical laboratory technician**

In order to obtain CME credits, participants must:

- *Attend 100% of the sessions indicated in the programme*
- *Fill in the personal data form, the form evaluating the event, and the learning questionnaire and give them to the Organizational Secretariat at the end of the Congress.*

The CME certificate will be sent by mail after the Congress to the address given on the personal data form.

REGISTRATION

The registration is free and includes:

- Participation in the conference work • Congress Kit
- Certificate of Attendance • CME credits
- Welcome coffee and lunch as scheduled

REGISTRATION INSTRUCTIONS

To register for the Congress you must fill in the form and send it to the Organizational Secretariat within **20 January 2015**. The Organizational Secretariat will inform the participant that he or she has been registered for the Congress.



Registration Form

Fill in using capital letters and send with payment to:
 NADIREX INTERNATIONAL s.r.l.
 Via Riviera, 39-27100 Pavia
 Fax +39.0382.525736 - info@nadirex.com

PLEASE COMPLETE THE FOLLOWING DETAILS

- PHISYCIAN
 BIOLOGIST
 NURSE
 BIOMEDICAL LABORATORY TECHNICIAN

Name Surname

Profession Discipline

Specialized

Clinic/Institute

Division/Department

Address

Postal Code Town/City Province

Tel. Fax

Mobile Tel.

E-mail

I authorise the use of my personal data in accordance with Legislative Decree 196/2003

Date Signature

CON IL CONTRIBUTO
EDUCAZIONALE DI

AMGEN[®]

Amgen Dompé S.p.A.



Bristol-Myers Squibb



 **NOVARTIS**



We Innovate Healthcare